Nantkwest Inc (NK) was Initiated by Raymond James to “Mkt Perform”. Raymond James advised their investors in a research report released on Jun 2, 2016.
Many Wall Street Analysts have commented on Nantkwest Inc. Shares were Reiterated by Canaccord Genuity on Apr 4, 2016 to “Buy” and Lowered the Price Target to $ 18 from a previous price target of $20 .Shares were Reiterated by FBR Capital on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 29 from a previous price target of $30 .
On the company’s financial health, Nantkwest Inc reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.43 based on the information available during the earnings call on Nov 12, 2015. Analyst had a consensus of $-0.12. The company had revenue of $.01 million for the quarter, compared to analysts expectations of $.10 million. The company’s revenue was down -92.3 % compared to the same quarter last year.
Nantkwest Inc opened for trading at $7.58 and hit $7.97 on the upside on Wednesday, eventually ending the session at $7.81, with a gain of 2.49% or 0.19 points. The heightened volatility saw the trading volume jump to 3,90,858 shares. Company has a market cap of $640 M.
In a different news, on Dec 11, 2015, Angela Wilson (CFO) purchased 3,265 shares at $15.31 per share price. According to the SEC, on Aug 25, 2015, 13 Ventures, Llc Mp (CEO) purchased 450,000 shares at $23.00 per share price. On Aug 25, 2015, Steve Gorlin (director) sold 450,000 shares at $23.00 per share price, according to the Form-4 filing with the securities and exchange commission.
NantKwest Inc. formerly Conkwest Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer infectious diseases and inflammatory diseases. The Company’s product candidates include aNK haNK and taNK. The Company’s aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers such as polyomavirus induced Merkel cell carcinoma human Papillomavirus (HPV) induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16 a receptor that allows direct binding of NK cells to antibodies. The Company’s taNK product candidate targets specific antigens on the surface of abnormal cells including CD33 EGFR HER2/neu PDL1 and PSMA.